Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Incannex Healthcare reports quarterly loss per share of $0.15
Incannex Healthcare reported earnings per share of -$0.15 for the quarter ended June 30, 2026, presented at the finance conference on September 25, 2026. For the fiscal year it reported a loss per share of -$1.66, after -$40.50 in the prior year. » Altro su finanzen.net
Incannex Healthcare receives AUD 6.04m tax credit and expects a further AUD 5.1m
Incannex Healthcare has received a payment of AUD 6,039,162.43 from the Australian research and development incentive program and expects additional tax credits of AUD 5.1 million in 2026. The expected total proceeds from this non-dilutive capital therefore exceed AUD 11.1 million. The funds are intended to support further development of clinical programs such as IHL-42X and PSX-001 and capital allocation measures, including a share buyback program. » Altro su de.investing.com
Incannex starts DReAMzz study to optimise dosing of IHL-42X for obstructive sleep apnea
Incannex has begun the clinical DReAMzz crossover study to optimise dosing of IHL-42X (dronabinol/acetazolamide) for the treatment of obstructive sleep apnea. The company lists 14 identified study centres, completed manufacturing of the investigational products, and secured import/export approvals and distribution agreements to activate the sites. IHL-42X has Fast Track status with the FDA; Incannex notes rapid cash burn despite positive balance-sheet metrics and says adequate funding is critical (market capitalization: $53.8m; share price: $3.90). » Altro su de.investing.com
Incannex reactivates stock buyback program after pause
Incannex resumed its stock buyback program after a period of inactivity over the last two trading days and says it will opportunistically continue repurchasing shares. The biopharmaceutical company reports about $75 million in cash following a financing round, is debt-free and shows a very high short-term liquidity ratio (Current Ratio 48.27). The stock trades at $3.41, below the InvestingPro fair value of $4.06; as of 31.12.2025 roughly $18.5 million remained available for buybacks. Incannex stresses the decision reflects a discrepancy between market valuation and its financial position as well as progress in the clinical pipeline (including IHL-42X, PSX-001). » Altro su de.investing.com
Incannex has about $75m in cash after financing round and is debt-free
Incannex has roughly $75 million in cash following a financing round led by institutional healthcare investors and carries no debt. Market capitalization is around $46 million, which together with the liquidity position results in a negative enterprise value. The proceeds are intended primarily to fund the phase‑2 dosing‑optimization study DReAMzz for IHL‑42X (obstructive sleep apnea); IHL‑42X has FDA Fast Track status. The company plans dose administrations in the coming months, has an approved share buyback program, and is concurrently advancing development of PSX‑001 (oral synthetic psilocybin). » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | 2023 | YoY |
|---|---|---|
| Ricavi | 618,83K | 20,15% |
| Utile lordo | 618,83K | 21,13% |
| Utile netto | -12,19 Mln | 122,65% |
| EBITDA | -10,79 Mln | 361,24% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 8,73 Mln € |
Numero di azioni | 347,71 Mln |
Massimo/minimo a 52 settimane | 0,17 € - 0,0251 € |
| Dividendi | No |
Beta | 2,09 |
Rapporto P/E | -2,88 |
Rapporto PEG | -0,03 |
Rapporto P/B | 0,37 |
Rapporto P/S | 0,00 |
Profilo aziendale
Incannex Healthcare Limited si occupa della ricerca, dello sviluppo e della vendita di prodotti medicinali a base di cannabinoidi in Australia. Offre prodotti a base di cannabinoidi di grado farmaceutico con il marchio Incannex. I prodotti dell'azienda includono IHL-42X, in fase II di sperimentazione clinica per l'apnea ostruttiva del sonno; IHL-216A, per la lesione cerebrale traumatica; e IHL-675A, una combinazione di idrossiclorochina e cannabidiolo per la prevenzione e il trattamento di patologie infiammatorie polmonari, come la sindrome da distress respiratorio acuto, la broncopneumopatia cronica ostruttiva, l'asma e la bronchite, nonché l'artrite reumatoide e le malattie infiammatorie intestinali. Collabora con The Alfred Hospital e Novotech al programma clinico di IHL-42X per l'apnea ostruttiva del sonno, e con il Monash Trauma Group del Dipartimento di Neuroscienze della Monash University per condurre uno studio sull'effetto protettivo di IHL-216A nelle commozioni cerebrali sportive. La società era precedentemente nota come Impression Healthcare Limited e ha cambiato denominazione in Incannex Healthcare Limited nel giugno 2020. Incannex Healthcare Limited è stata costituita nel 2001 e ha sede a Sydney, in Australia.
| Nome | INCANNEX HEALTHCARE LTD. |
| CEO | Joel Bradley Latham |
| Sede centrale | Sydney,
nsw Australia |
| Sito web | |
| Quotazione in borsa | 23/05/2007 |
| Dipendenti | 3 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Australian Securities Exchange Ltd | IHL.AX |